P Pharming Group NV
P
Suletud
1.1 -2.57
Ülevaade
Aktsiahinna muutus
24h
Min
1.096
Max
1.133
Sissetulek | -10M -5.1M |
|---|---|
Müük | -36M 71M |
P/E Sektori keskmine | 55.3 51.415 |
Aktsiakasum | 0.01 |
Kasumimarginaal | -7.196 |
Töötajad | 407 |
EBITDA | -4.8M -2.1M |
Järgmine tulemuste avaldamine | 30. juuli 2026 |
|---|
Turukapital | -227M 781M |
|---|---|
Eelmine avamishind | 3.67 |
Eelmine sulgemishind | 1.1 |
Pharming Group NV Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pharming Group NV Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
